{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T14:51:51Z","timestamp":1785595911866,"version":"3.56.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Taiho Oncology, Inc."},{"name":"Taiho Pharmaceutical Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00280-021-04308-z","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T01:02:37Z","timestamp":1623027757000},"page":"485-497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine\/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment"],"prefix":"10.1007","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8154-957X","authenticated-orcid":false,"given":"Muhammad Wasif","family":"Saif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos R.","family":"Becerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan G.","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazar","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smitha","family":"Krishnamurthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Rudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale R.","family":"Shepard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Skopek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Sramek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojan","family":"Zaric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuo","family":"Yamamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim A.","family":"Benhadji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"issue":"4","key":"4308_CR1","first-page":"545","volume":"13","author":"T Emura","year":"2004","unstructured":"Emura T, Murakami Y, Nakagawa F, Fukushima M, Kitazato K (2004) A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med 13(4):545\u2013549","journal-title":"Int J Mol Med"},{"issue":"2","key":"4308_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10637-016-0409-9","volume":"35","author":"JM Cleary","year":"2017","unstructured":"Cleary JM, Rosen LS, Yoshida K, Rasco D, Shapiro GI, Sun W (2017) A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone. Invest New Drugs 35(2):189\u2013197","journal-title":"Invest New Drugs"},{"issue":"5","key":"4308_CR3","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00280-015-2850-4","volume":"76","author":"JC Bendell","year":"2015","unstructured":"Bendell JC, Rosen LS, Mayer RJ et al (2015) Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. Cancer Chemother Pharmacol 76(5):925\u2013932","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"4308_CR4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/bjc.2012.274","volume":"107","author":"T Doi","year":"2012","unstructured":"Doi T, Ohtsu A, Yoshino T et al (2012) Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer 107(3):429\u2013434","journal-title":"Br J Cancer"},{"issue":"6","key":"4308_CR5","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/cncr.22125","volume":"107","author":"DS Hong","year":"2006","unstructured":"Hong DS, Abbruzzese JL, Bogaard K et al (2006) Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer 107(6):1383\u20131390","journal-title":"Cancer"},{"issue":"5","key":"4308_CR6","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10637-008-9142-3","volume":"26","author":"MJ Overman","year":"2008","unstructured":"Overman MJ, Varadhachary G, Kopetz S et al (2008) Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs 26(5):445\u2013454","journal-title":"Invest New Drugs"},{"key":"4308_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.lungcan.2016.06.023","volume":"100","author":"G Scagliotti","year":"2016","unstructured":"Scagliotti G, Nishio M, Satouchi M et al (2016) A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy. Lung Cancer 100:20\u201323","journal-title":"Lung Cancer"},{"issue":"3","key":"4308_CR8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00280-016-2965-2","volume":"77","author":"JJ Lee","year":"2016","unstructured":"Lee JJ, Seraj J, Yoshida K et al (2016) Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry. Cancer Chemother Pharmacol 77(3):515\u2013526","journal-title":"Cancer Chemother Pharmacol"},{"key":"4308_CR9","volume-title":"LONSURF (trifluridine and tipiracil) tablets, for oral use [prescribing information]","author":"Taiho Oncology","year":"2019","unstructured":"Taiho Oncology (2019) LONSURF (trifluridine and tipiracil) tablets, for oral use [prescribing information]. Taiho Oncology Inc, Princeton, NJ"},{"issue":"20","key":"4308_CR10","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372(20):1909\u20131919","journal-title":"N Engl J Med"},{"issue":"11","key":"4308_CR11","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara K, Doi T, Dvorkin M et al (2018) Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 19(11):1437\u20131448","journal-title":"Lancet Oncol"},{"issue":"4","key":"4308_CR12","doi-asserted-by":"publisher","first-page":"e000091","DOI":"10.1136\/esmoopen-2016-000091","volume":"1","author":"V Launay-Vacher","year":"2016","unstructured":"Launay-Vacher V, Janus N, Deray G (2016) Renal insufficiency and cancer treatments. ESMO Open 1(4):e000091","journal-title":"ESMO Open"},{"issue":"6","key":"4308_CR13","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/cncr.22904","volume":"110","author":"V Launay-Vacher","year":"2007","unstructured":"Launay-Vacher V, Oudard S, Janus N et al (2007) Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 110(6):1376\u20131384","journal-title":"Cancer"},{"issue":"2 Suppl 1","key":"4308_CR14","first-page":"S1","volume":"39","author":"National Kidney Foundation","year":"2002","unstructured":"National Kidney Foundation (2002) K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1-266","journal-title":"Am J Kidney Dis"},{"key":"4308_CR15","unstructured":"US FDA Guidance Document (2010) Pharmacokinetics in patients with impaired renal function: study design, data analysis and impact on dosing and labeling. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/pharmacokinetics-patients-impaired-renal-function-study-design-data-analysis-and-impact-dosing-and. Accessed 27 April 2021"},{"issue":"10","key":"4308_CR16","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/S1470-2045(12)70345-5","volume":"13","author":"T Yoshino","year":"2012","unstructured":"Yoshino T, Mizunuma N, Yamazaki K et al (2012) TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13(10):993\u20131001","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"4308_CR17","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1200\/JCO.2016.34.15_suppl.3547","volume":"34","author":"RJ Mayer","year":"2016","unstructured":"Mayer RJ, Ohtsu A, Yoshino T et al (2016) Efficacy and safety results in patients with impaired renal and hepatic function in the RECOURSE trial. J Clin Oncol 34(15_suppl):3547","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"4308_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1200\/JCO.2020.38.4_suppl.145","volume":"38","author":"B George","year":"2020","unstructured":"George B, Cutsem EV, Hochster HS et al (2020) Analysis of hematologic adverse events (HeAEs) in trifluridine\/tipiracil (FTD\/TPI)-treated patients (pts) with or without renal\/hepatic impairment (RI\/HI): Pooled safety analyses from TAGS and RECOURSE. J Clin Oncol 38(4_suppl):145","journal-title":"J Clin Oncol"},{"issue":"6","key":"4308_CR19","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/bcp.13856","volume":"85","author":"MW Saif","year":"2019","unstructured":"Saif MW, Rosen L, Rudek MA et al (2019) Open-label study to evaluate trifluridine\/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment. Br J Clin Pharmacol 85(6):1239\u20131246","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"4308_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/00912700022008658","volume":"40","author":"S Ibrahim","year":"2000","unstructured":"Ibrahim S, Honig P, Huang SM, Gillespie W, Lesko LJ, Williams RL (2000) Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives. J Clin Pharmacol 40(1):31\u201338","journal-title":"J Clin Pharmacol"},{"key":"4308_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000496369","volume":"198","author":"H Honda","year":"2019","unstructured":"Honda H, Hosaka N, Ganz T, Shibata T (2019) Iron metabolism in chronic kidney disease patients. Contrib Nephrol 198:103\u2013111","journal-title":"Contrib Nephrol"},{"issue":"15_suppl","key":"4308_CR22","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1200\/jco.2015.33.15_suppl.2579","volume":"33","author":"JM Cleary","year":"2015","unstructured":"Cleary JM, Mayer RJ, Van Cutsem E et al (2015) Population pharmacokinetic (PK) analysis of TAS-102 in patients (pts) with metastatic colorectal cancer (mCRC): results from 3 phase 1 trials and the phase 3 RECOURSE trial. J Clin Oncol 33(15_suppl):2579","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04308-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-021-04308-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-021-04308-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T10:12:07Z","timestamp":1628590327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-021-04308-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["4308"],"URL":"https:\/\/doi.org\/10.1007\/s00280-021-04308-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,7]]},"assertion":[{"value":"29 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.W.S. reports research funding from Incyte, Lexicon, NGM Bio, Nouscom, Tesaro, and Yivia. C.R.B. is part of the speaker bureau for Taiho Oncology Inc. M.G.F. received research grant funding (to institution) from Amgen, AstraZeneca, and Novartis; has served on the advisory board of Amgen, Array Biopharma, Bayer, and Pfizer; is part of the speakers bureau for Amgen and Guardant360, and reports honoraria from Amgen. M.A.R. received research funding from Taiho Oncology, Inc, during the conduct of the study and from Celgene Corporation and the National Cancer Institute, outside the submitted work. K.H., I.Y., K.A.B., and Y.H are employees of Taiho Oncology, Inc. K.A.B. is a former employee and a stockholder of Eli Lilly. L.R. received research funding from Taiho Oncology, Inc. W.S., L.P., S.K., T.J.G., D.R.S., J.S., V.S., and B.Z have no financial disclosures to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the Declaration of Helsinki. Approval was granted from the review board or ethics committee of each institution.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}